Wednesday, June 22, 2011
NanoBio Corp., of Ann Arbor, Mich., started a second tolerability and immunogenicity study designed to test and further optimize its nanoemulsion-based intranasal vaccine adjuvant. The Phase Ib study will test the adjuvant combined with Fluzone (Sanofi). Mucosal, systemic humoral and cellular-mediated immune responses will be examined.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.